Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Steven Grant

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Phenomena

Drug Synergism

Physiology

Disorders

Leukemia

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
140
Dent, Paul
48
Dai, Yun
47
Rahmani, Mohamed
45
Fisher, Paul
39
Yacoub, Adly
26
Jarvis, David
25
Mitchell, Clint
19
Park, Margaret
18
Rosato, Roberto
18
Hagan, Michael
18
Curiel, David
17
Almenara, Jorge
16
Wang, Zhiliang
16
Yu, Chunrong
15
Qiao, Liang

Sign-in to see all Coauthors

Publications

TOP 3
Chen Shuang; Dai Yun; Pei Xin-Yan; Grant Steven
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Li Qianbin; Al-Ayoubi Adnan; Guo Tailiang; Zheng Hui; Sarkar Aurijit; Nguyen Tri; Eblen Scott T; Grant Steven; Kellogg Glen E; Zhang Shijun
Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.
Rambal A A; Panaguiton Z L G; Kramer L; Grant S; Harada H
MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Steven Grant (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Chen Shuang; Dai Yun; Pei Xin-Yan; Grant Steven
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Molecular and cellular biology 2009;29(23):6149-69.
2009: Li Qianbin; Al-Ayoubi Adnan; Guo Tailiang; Zheng Hui; Sarkar Aurijit; Nguyen Tri; Eblen Scott T; Grant Steven; Kellogg Glen E; Zhang Shijun
Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.
Bioorganic & medicinal chemistry letters 2009;19(21):6042-6.
2009: Rambal A A; Panaguiton Z L G; Kramer L; Grant S; Harada H
MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(10):1744-54.
2009: Martin Aditi Pandya; Park Margaret A; Mitchell Clint; Walker Teneille; Rahmani Mohamed; Thorburn Andrew; Häussinger Dieter; Reinehr Roland; Grant Steven; Dent Paul
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Molecular pharmacology 2009;76(2):327-41.
2009: Walker Teneille; Mitchell Clint; Park Margaret A; Yacoub Adly; Graf Martin; Rahmani Mohamed; Houghton Peter J; Voelkel-Johnson Christina; Grant Steven; Dent Paul
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Molecular pharmacology 2009;76(2):342-55.
2009: Dent Paul; Curiel David T; Fisher Paul B; Grant Steven
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(3):65-73.
2009: Dasmahapatra Girija; Lembersky Dmitry; Rahmani Mohamed; Kramer Lora; Friedberg Jonathan; Fisher Richard I; Dent Paul; Grant Steven
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Cancer biology & therapy 2009;8(9):808-19.
2009: Dent Paul; Grant Steven; Fisher Paul B; Curiel David T
PI3K: A rational target for ovarian cancer therapy?
Cancer biology & therapy 2009;8(1):27-30.
2008: Grant Steven
Is the focus moving toward a combination of targeted drugs?
Best practice & research. Clinical haematology 2008;21(4):629-37.
2008: Rosato Roberto R; Almenara Jorge A; Maggio Sonia C; Coe Stefanie; Atadja Peter; Dent Paul; Grant Steven
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Molecular cancer therapeutics 2008;7(10):3285-97.
2008: Park Margaret A; Zhang Guo; Martin Aditi Pandya; Hamed Hossein; Mitchell Clint; Hylemon Philip B; Graf Martin; Rahmani Mohamed; Ryan Kevin; Liu Xiang; Spiegel Sarah; Norris James; Fisher Paul B; Grant Steven; Dent Paul
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Cancer biology & therapy 2008;7(10):1648-62.
2008: Park Margaret A; Zhang Guo; Norris James; Hylemon Philip B; Fisher Paul B; Grant Steven; Dent Paul
Regulation of autophagy by ceramide-CD95-PERK signaling.
Autophagy 2008;4(7):929-31.
2008: Park Margaret A; Zhang Guo; Mitchell Clint; Rahmani Mohamed; Hamed Hossein; Hagan Michael P; Yacoub Adly; Curiel David T; Fisher Paul B; Grant Steven; Dent Paul
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Molecular cancer therapeutics 2008;7(9):2633-48.
2008: Zhang Guo; Park Margaret A; Mitchell Clint; Hamed Hossein; Rahmani Mohamed; Martin Aditi Pandya; Curiel David T; Yacoub Adly; Graf Martin; Lee Ray; Roberts John D; Fisher Paul B; Grant Steven; Dent Paul
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5385-99.
2008: Grant Steven
Cotargeting survival signaling pathways in cancer.
The Journal of clinical investigation 2008;118(9):3003-6.
2008: Dent Paul; Yacoub Adly; Park Margaret; Sarkar Devanand; Shah Khalid; Curiel David T; Grant Steven; Fisher Paul B
Searching for a cure: gene therapy for glioblastoma.
Cancer biology & therapy 2008;7(9):1335-40.
2008: Dai Yun; Chen Shuang; Pei Xin-Yan; Almenara Jorge A; Kramer Lora B; Venditti Charis A; Dent Paul; Grant Steven
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Blood 2008;112(6):2439-49.
2008: Zhang Guo; Park Margaret A; Mitchell Clint; Walker Teneille; Hamed Hossein; Studer Elaine; Graf Martin; Rahmani Mohamed; Gupta Seema; Hylemon Philip B; Fisher Paul B; Grant Steven; Dent Paul
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.
The Journal of biological chemistry 2008;283(36):24343-58.
2008: Martin Aditi Pandya; Miller Anna; Emad Luni; Rahmani Mohammed; Walker Teneille; Mitchell Clint; Hagan Michael P; Park Margaret A; Yacoub Adly; Fisher Paul B; Grant Steven; Dent Paul
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Molecular pharmacology 2008;74(3):807-22.
2008: Paugh Steven W; Paugh Barbara S; Rahmani Mohamed; Kapitonov Dmitri; Almenara Jorge A; Kordula Tomasz; Milstien Sheldon; Adams Jeffrey K; Zipkin Robert E; Grant Steven; Spiegel Sarah
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Blood 2008;112(4):1382-91.
2008: Dai Yun; Chen Shuang; Venditti Charis A; Pei Xin-Yan; Nguyen Tri K; Dent Paul; Grant Steven
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Blood 2008;112(3):793-804.
2008: Yacoub Adly; Hamed Hossein; Emdad Luni; Dos Santos Wagner; Gupta Pankaj; Broaddus William C; Ramakrishnan Viswanathan; Sarkar Devanand; Shah Khalid; Curiel David T; Grant Steven; Fisher Paul B; Dent Paul
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.
Cancer biology & therapy 2008;7(6):917-33.
2008: Park Margaret A; Yacoub Adly; Sarkar Devanand; Emdad Luni; Rahmani Mohammed; Spiegel Sarah; Koumenis Costas; Graf Martin; Curiel David T; Grant Steven; Fisher Paul B; Dent Paul
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells.
Autophagy 2008;4(4):513-5.
2008: Hamed Hossein; Mitchell Clint; Park Margaret A; Hanna David; Martin Aditi Pandya; Harrison Benjamin; Hawkins William; Curiel David A; Fisher Paul B; Grant Steven; Yacoub Adly; Hagan Michael P; Dent Paul
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Cancer biology & therapy 2008;7(4):587-93.
2008: Park Margaret A; Curiel David T; Koumenis Costas; Graf Martin; Chen Ching-Shih; Fisher Paul B; Grant Steven; Dent Paul
PERK-dependent regulation of HSP70 expression and the regulation of autophagy.
Autophagy 2008;4(3):364-7.
2008: Park Margaret A; Yacoub Adly; Rahmani Mohammed; Zhang Guo; Hart Lori; Hagan Michael P; Calderwood Stuart K; Sherman Michael Y; Koumenis Costas; Spiegel Sarah; Chen Ching-Shih; Graf Martin; Curiel David T; Fisher Paul B; Grant Steven; Dent Paul
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
Molecular pharmacology 2008;73(4):1168-84.
2008: Hamed Hossein; Hawkins William; Mitchell Clint; Gilfor Donna; Zhang Guo; Pei Xin-Yan; Dai Yun; Hagan Michael P; Roberts John D; Yacoub Adly; Grant Steven; Dent Paul
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
Molecular cancer therapeutics 2008;7(3):616-29.
2008: Yacoub Adly; Gupta Pankaj; Park Margaret A; Rhamani Mohammed; Hamed Hossein; Hanna David; Zhang Guo; Sarkar Devanand; Lebedeva Irina V; Emdad Luni; Koumenis Costas; Curiel David T; Grant Steven; Fisher Paul B; Dent Paul
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.
Molecular cancer therapeutics 2008;7(2):314-29.
2008: Yacoub Adly; Park Margaret A; Gupta Pankaj; Rahmani Mohammed; Zhang Guo; Hamed Hossein; Hanna David; Sarkar Devanand; Lebedeva Irina V; Emdad Luni; Sauane Moira; Vozhilla Nicollaq; Spiegel Sarah; Koumenis Costas; Graf Martin; Curiel David T; Grant Steven; Fisher Paul B; Dent Paul
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.
Molecular cancer therapeutics 2008;7(2):297-313.
2008: Dai Yun; Chen Shuang; Kramer Lora B; Funk Vanessa L; Dent Paul; Grant Steven
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):549-58.
2007: Mitchell Clint; Park Maragret A; Zhang Guo; Yacoub Adly; Curiel David T; Fisher Paul B; Roberts John D; Grant Steven; Dent Paul
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Molecular cancer therapeutics 2007;6(12 Pt 1):3101-12.
2007: Rosato Roberto R; Almenara Jorge A; Coe Stefanie; Grant Steven
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Cancer research 2007;67(19):9490-500.
2007: Rahmani Mohamed; Nguyen Tri K; Dent Paul; Grant Steven
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Molecular pharmacology 2007;72(3):788-95.
2007: Mitchell Clint; Kabolizadeh Peyman; Ryan John; Roberts John D; Yacoub Adly; Curiel David T; Fisher Paul B; Hagan Michael P; Farrell Nicholas P; Grant Steven; Dent Paul
Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling.
Molecular pharmacology 2007;72(3):704-14.
2007: Pei Xin-Yan; Dai Yun; Tenorio Sarah; Lu Jianghua; Harada Hisashi; Dent Paul; Grant Steven
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Blood 2007;110(6):2092-101.
2007: Rahmani Mohamed; Davis Eric Maynard; Crabtree Timothy Ryan; Habibi Joseph Reza; Nguyen Tri K; Dent Paul; Grant Steven
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
Molecular and cellular biology 2007;27(15):5499-513.
2007: Dasmahapatra Girija; Yerram Nitin; Dai Yun; Dent Paul; Grant Steven
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4280-90.
2007: Grant Steven; Dent Paul
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Current drug targets 2007;8(6):751-9.
2007: Dai Yun; Khanna Payal; Chen Shuang; Pei Xin-Yan; Dent Paul; Grant Steven
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Blood 2007;109(10):4415-23.
2007: Nguyen Tri K; Rahmani Mohamed; Harada Hisashi; Dent Paul; Grant Steven
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Blood 2007;109(9):4006-15.
2007: Dai Yun; Grant Steven
Targeting multiple arms of the apoptotic regulatory machinery.
Cancer research 2007;67(7):2908-11.
2007: Fang Youwen; Studer Elaine; Mitchell Clint; Grant Steven; Pandak William M; Hylemon Philip B; Dent Paul
Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling.
Molecular pharmacology 2007;71(4):1122-8.
2007: Valerie Kristoffer; Yacoub Adly; Hagan Michael P; Curiel David T; Fisher Paul B; Grant Steven; Dent Paul
Radiation-induced cell signaling: inside-out and outside-in.
Molecular cancer therapeutics 2007;6(3):789-801.
2007: Rosato Roberto R; Almenara Jorge A; Kolla Sarah S; Maggio Sonia C; Coe Stefanie; Giménez Maria S; Dent Paul; Grant Steven
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Molecular cancer therapeutics 2007;6(2):692-702.
2007: Mitchell Clint; Park Margaret A; Zhang Guo; Han Song Iy; Harada Hisashi; Franklin Richard A; Yacoub Adly; Li Pin-Lan; Hylemon Philip B; Grant Steven; Dent Paul
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.
Molecular cancer therapeutics 2007;6(2):618-32.
2007: Chen Shuang; Dai Yun; Harada Hisashi; Dent Paul; Grant Steven
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Cancer research 2007;67(2):782-91.
2007: Yacoub Adly; Hawkins William; Hanna David; Young Hong; Park Margaret A; Grant Mark; Roberts John D; Curiel David T; Fisher Paul B; Valerie Kristoffer; Grant Steven; Hagan Michael P; Dent Paul
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
Molecular pharmacology 2007;71(1):259-75.
2007: Dent Paul; Hylemon Philip B; Grant Steven; Fisher Paul B
Approaches for monitoring signal transduction changes in normal and cancer cells.
Methods in molecular biology (Clifton, N.J.) 2007;383():259-76.
2006: Yacoub Adly; Miller Anna; Caron Ruben W; Qiao Liang; Curiel David A; Fisher Paul B; Hagan Michael P; Grant Steven; Dent Paul
Radiotherapy-induced signal transduction.
Endocrine-related cancer 2006;13 Suppl 1():S99-114.
2006: Pei Xin-Yan; Li Weiqun; Dai Yun; Dent Paul; Grant Steven
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Molecular pharmacology 2006;70(6):1965-73.
2006: Roberts John D; Smith Mitchell R; Feldman Eric J; Cragg Louise; Millenson Michael M; Roboz Gail J; Honeycutt Connie; Thune Rose; Padavic-Shaller Kristin; Carter W Hans; Ramakrishnan Viswanathan; Murgo Anthony J; Grant Steven
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5809-16.
2006: Yacoub Adly; Gilfor Donna; Hawkins William; Park Margaret A; Hanna David; Hagan Michael P; Curiel David T; Fisher Paul B; Grant Steven; Dent Paul
MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.
Cancer biology & therapy 2006;5(10):1332-9.
2006: Dasmahapatra Girija; Nguyen Tri K; Dent Paul; Grant Steven
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Leukemia research 2006;30(10):1263-72.
2006: Jia Wentao; Hegde Venkatesh L; Singh Narendra P; Sisco Daniel; Grant Steven; Nagarkatti Mitzi; Nagarkatti Prakash S
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.
Molecular cancer research : MCR 2006;4(8):549-62.
2006: Gao Ning; Kramer Lora; Rahmani Mohamed; Dent Paul; Grant Steven
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Molecular pharmacology 2006;70(2):645-55.
2006: Yacoub Adly; Park Margaret A; Hanna David; Hong Young; Mitchell Clint; Pandya Aditi P; Harada Hisashi; Powis Garth; Chen Ching-Shih; Koumenis Costas; Grant Steven; Dent Paul
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Molecular pharmacology 2006;70(2):589-603.
2006: Nguyen Tri K; Rahmani Mohamed; Gao Ning; Kramer Lora; Corbin Amie S; Druker Brian J; Dent Paul; Grant Steven
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2239-47.
2006: Dai Yun; Grant Steven
CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins.
Cancer biology & therapy 2006;5(2):171-3.
2006: Dai Yun; Hamm Tracy E; Dent Paul; Grant Steven
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
Cell cycle (Georgetown, Tex.) 2006;5(4):437-46.
2006: Dasmahapatra Girija; Almenara Jorge A; Grant Steven
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Molecular pharmacology 2006;69(1):288-98.
2006: Rosato Roberto R; Maggio Sonia C; Almenara Jorge A; Payne Shawn G; Atadja Peter; Spiegel Sarah; Dent Paul; Grant Steven
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Molecular pharmacology 2006;69(1):216-25.
2006: Dasmahapatra Girija; Rahmani Mohamed; Dent Paul; Grant Steven
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Blood 2006;107(1):232-40.
2006: Gao Ning; Rahmani Mohamed; Shi Xianglin; Dent Paul; Grant Steven
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
Blood 2006;107(1):241-9.
2005: Hawkins William; Mitchell Clint; McKinstry Robert; Gilfor Donna; Starkey James; Dai Yun; Dawson Kathy; Ramakrishnan Viswanathan; Roberts John D; Yacoub Adly; Grant Steven; Dent Paul
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
Cancer biology & therapy 2005;4(11):1275-84.
2005: Rosato Roberto R; Almenara Jorge A; Maggio Sonia C; Atadja Peter; Craig Ruth; Vrana Julie; Dent Paul; Grant Steven
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Molecular cancer therapeutics 2005;4(11):1772-85.
2005: Dent Paul; Han Song Iy; Mitchell Clint; Studer Elaine; Yacoub Adly; Grandis Jennifer; Grant Steven; Krystal Geoffrey W; Hylemon Philip B
Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.
Biochemical pharmacology 2005;70(11):1685-96.
2005: Rahmani Mohamed; Davis Eric Maynard; Bauer Cheryl; Dent Paul; Grant Steven
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
The Journal of biological chemistry 2005;280(42):35217-27.
2005: Yu C; Dasmahapatra G; Dent P; Grant S
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1579-89.
2005: Rosato Roberto R; Grant Steven
Histone deacetylase inhibitors: insights into mechanisms of lethality.
Expert opinion on therapeutic targets 2005;9(4):809-24.
2005: Dai Yun; Rahmani Mohamed; Dent Paul; Grant Steven
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Molecular and cellular biology 2005;25(13):5429-44.
2005: Dent Paul; Yacoub Adly; Grant Steven; Curiel David T; Fisher Paul B
MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?
Journal of cellular biochemistry 2005;95(4):712-9.
2005: Pei Xin-Yan; Dai Yun; Rahmani Mohamed; Li Weiqun; Dent Paul; Grant Steven
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4589-600.
2005: Dent Paul; Yacoub Adly; Grant Steven
DMC: novel celecoxib derivatives to rap cancer.
Cancer biology & therapy 2005;4(5):583-4.
2005: Gao Ning; Rahmani Mohamed; Dent Paul; Grant Steven
2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process.
Oncogene 2005;24(23):3797-809.
2005: Rahmani Mohamed; Reese Erin; Dai Yun; Bauer Cheryl; Kramer Lora B; Huang Mei; Jove Richard; Dent Paul; Grant Steven
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Molecular pharmacology 2005;67(4):1166-76.
2005: Rahmani Mohamed; Reese Erin; Dai Yun; Bauer Cheryl; Payne Shawn G; Dent Paul; Spiegel Sarah; Grant Steven
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Cancer research 2005;65(6):2422-32.
2005: Hahn Michael; Li Weiqun; Yu Chunrong; Rahmani Mohamed; Dent Paul; Grant Steven
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Molecular cancer therapeutics 2005;4(3):457-70.
2005: Carón Rubén W; Yacoub Adly; Mitchell Clint; Zhu Xiaoyu; Hong Young; Sasazuki Takehiko; Shirasawa Senji; Hagan Michael P; Grant Steven; Dent Paul
Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2005;4(3):456-64.
2005: Carón Rubén W; Yacoub Adly; Li Min; Zhu Xiaoyu; Mitchell Clint; Hong Young; Hawkins William; Sasazuki Takehiko; Shirasawa Senji; Kozikowski Alan P; Dennis Philip A; Hagan Michael P; Grant Steven; Dent Paul
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
Molecular cancer therapeutics 2005;4(2):257-70.
2005: Carón Rubén W; Yacoub Adly; Zhu Xiaoyu; Mitchell Clint; Han Song Iy; Sasazuki Takehiko; Shirasawa Senji; Hagan Michael P; Grant Steven; Dent Paul
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
Molecular cancer therapeutics 2005;4(2):243-55.
2005: Dai Yun; Rahmani Mohamed; Pei Xin-Yan; Khanna Payal; Han Song Iy; Mitchell Clint; Dent Paul; Grant Steven
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Blood 2005;105(4):1706-16.
2004: Pei Xin-Yan; Dai Yun; Grant Steven
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Molecular cancer therapeutics 2004;3(12):1513-24.
2004: Bouton L Andrew; Ramirez Carlos D; Bailey Daniel P; Yeatman C Fitzhugh; Yue Joyce; Wright Harry V; Domen Jos; Rosato Roberto R; Grant Steven; Fischer-Stenger Krista; Ryan John J
Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion.
Experimental hematology 2004;32(12):1137-45.
2004: Grant S
The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(12):1931-3.
2004: Dent Paul; Grant Steven
Irofulven: resurgence for alkylating therapy in cancer?
Cancer biology & therapy 2004;3(11):1143-4.
2004: Rosato R R; Dai Y; Almenara J A; Maggio S C; Grant S
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(11):1780-8.
2004: Ahmed Wesam; Rahmani Mohamed; Dent Paul; Grant Steven
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
Cell cycle (Georgetown, Tex.) 2004;3(10):1305-11.
2004: Fang Youwen; Han Song Iy; Mitchell Clint; Gupta Seema; Studer Elaine; Grant Steven; Hylemon Phillip B; Dent Paul
Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes.
Hepatology (Baltimore, Md.) 2004;40(4):961-71.
2004: Gao Ning; Dai Yun; Rahmani Mohamed; Dent Paul; Grant Steven
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Molecular pharmacology 2004;66(4):956-63.
2004: Yacoub Adly; Mitchell Clint; Hong Young; Gopalkrishnan Rahul V; Su Zhao-Zhong; Gupta Pankaj; Sauane Moria; Lebedeva Irina V; Curiel David T; Mahasreshti Parameshwar J; Rosenfeld Myrna R; Broaddus William C; James C David; Grant Steven; Fisher Paul B; Dent Paul
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Cancer biology & therapy 2004;3(8):739-51.
2004: Dai Yun; Rahmani Mohamed; Corey Seth J; Dent Paul; Grant Steven
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
The Journal of biological chemistry 2004;279(33):34227-39.
2004: Grant Steven; Dent Paul
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?
Molecular cancer therapeutics 2004;3(7):873-5.
2004: Dai Yun; Rahmani Mohamed; Pei Xin-Yan; Dent Paul; Grant Steven
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Blood 2004;104(2):509-18.
2004: Pei Xin-Yan; Dai Yun; Grant Steven
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3839-52.
2004: Yu Chunrong; Rahmani Mohamed; Dent Paul; Grant Steven
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Experimental cell research 2004;295(2):555-66.
2004: Maggio Sonia C; Rosato Roberto R; Kramer Lora B; Dai Yun; Rahmani Mohamed; Paik David S; Czarnik Ann C; Payne Shawn G; Spiegel Sarah; Grant Steven
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer research 2004;64(7):2590-600.
2004: Dai Yun; Pei Xin-Yan; Rahmani Mohamed; Conrad Daniel H; Dent Paul; Grant Steven
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Blood 2004;103(7):2761-70.
2004: Grant Steven; Dent Paul
Activation of MAP kinase pathways by TRAIL: don't expect the obvious.
Cancer biology & therapy 2004;3(3):302-4.
2004: Rosato Roberto R; Almenara Jorge A; Yu Chunrong; Grant Steven
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Molecular pharmacology 2004;65(3):571-81.
2004: Dai Yun; Grant Steven
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
Current oncology reports 2004;6(2):123-30.
2004: Han Song Iy; Studer Elaine; Gupta Seema; Fang Youwen; Qiao Liang; Li Weiqun; Grant Steven; Hylemon Philip B; Dent Paul
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes.
Hepatology (Baltimore, Md.) 2004;39(2):456-63.
2004: Yu Chunrong; Rahmani Mohamed; Almenara Jorge; Sausville Edward A; Dent Paul; Grant Steven
Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Oncogene 2004;23(7):1364-76.
2004: Rosato Roberto R; Grant Steven
Histone deacetylase inhibitors in clinical development.
Expert opinion on investigational drugs 2004;13(1):21-38.
2003: Rosato Roberto R; Almenara Jorge A; Dai Yun; Grant Steven
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Molecular cancer therapeutics 2003;2(12):1273-84.
2003: Rahmani Mohamed; Yu Chunrong; Dai Yun; Reese Erin; Ahmed Wesam; Dent Paul; Grant Steven
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Cancer research 2003;63(23):8420-7.
2003: Dai Yun; Dent Paul; Grant Steven
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Molecular pharmacology 2003;64(6):1402-9.
2003: Yacoub Adly; Han Song Iy; Caron Ruben; Gilfor Donna; Mooberry Susan; Grant Steven; Dent Paul
Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro.
Cancer biology & therapy 2003;2(6):670-6.
2003: Yu Chunrong; Rahmani Mohamed; Conrad Daniel; Subler Mark; Dent Paul; Grant Steven
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Blood 2003;102(10):3765-74.
2003: Dai Yun; Rahmani Mohamed; Grant Steven
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Oncogene 2003;22(46):7108-22.
2003: Litz Julie; Carlson Patricia; Warshamana-Greene G Sakuntala; Grant Steven; Krystal Geoffrey W
Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4586-94.
2003: Pei X-Y; Dai Y; Grant S
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(10):2036-45.
2003: Yu Chunrong; Subler Mark; Rahmani Mohamed; Reese Erin; Krystal Geoffrey; Conrad Daniel; Dent Paul; Grant Steven
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
Cancer biology & therapy 2003;2(5):544-51.
2003: Rahmani Mohamed; Yu Chunrong; Reese Erin; Ahmed Wesam; Hirsch Karen; Dent Paul; Grant Steven
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Oncogene 2003;22(40):6231-42.
2003: Dai Yun; Rahmani Mohamed; Grant Steven
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Cell cycle (Georgetown, Tex.) 2003;2(5):467-72.
2003: Dent Paul; Yacoub Adly; Fisher Paul B; Hagan Michael P; Grant Steven
MAPK pathways in radiation responses.
Oncogene 2003;22(37):5885-96.
2003: Jia Wentao; Yu Chunrong; Rahmani Mohamed; Krystal Geoffrey; Sausville Edward A; Dent Paul; Grant Steven
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Blood 2003;102(5):1824-32.
2003: Yacoub Adly; Mitchell Clint; Lister Andrea; Lebedeva Irina V; Sarkar Devanand; Su Zao-Zhong; Sigmon Carter; McKinstry Robert; Ramakrishnan Viswanathan; Qiao Liang; Broaddus William C; Gopalkrishnan Rahul V; Grant Steven; Fisher Paul B; Dent Paul
Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3272-81.
2003: Dai Yun; Grant Steven
Cyclin-dependent kinase inhibitors.
Current opinion in pharmacology 2003;3(4):362-70.
2003: Yacoub Adly; Mitchell Clint; Lebedeva Irina V; Sarkar Devanand; Su Zao-Zhong; McKinstry Robert; Gopalkrishnan Rahul V; Grant Steven; Fisher Paul B; Dent Paul
mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling.
Cancer biology & therapy 2003;2(4):347-53.
2003: Yacoub Adly; Mitchell Clint; Brannon Jessica; Rosenberg Elizabeth; Qiao Liang; McKinstry Robert; Linehan W Marston; Su Zao-shong; Sarkar Devanand; Lebedeva Irina V; Valerie Kristoffer; Gopalkrishnan Rahul V; Grant Steven; Fisher Paul B; Dent Paul
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.
Molecular cancer therapeutics 2003;2(7):623-32.
2003: Rosato Roberto R; Almenara Jorge A; Grant Steven
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Cancer research 2003;63(13):3637-45.
2003: Harada Hisashi; Grant Steven
Apoptosis regulators.
Reviews in clinical and experimental hematology 2003;7(2):117-38.
2003: Decker Roy H; Levin Jay; Kramer Lora B; Dai Yun; Grant Steven
Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
Biochemical pharmacology 2003;65(12):1997-2008.
2003: Yu Chunrong; Rahmani Mohamed; Almenara Jorge; Subler Mark; Krystal Geoffrey; Conrad Daniel; Varticovski Lubya; Dent Paul; Grant Steven
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Cancer research 2003;63(9):2118-26.
2003: Qiao Liang; Han Song Iy; Fang Youwen; Park Jong Sung; Gupta Seema; Gilfor Donna; Amorino George; Valerie Kristoffer; Sealy Linda; Engelhardt John F; Grant Steven; Hylemon Philip B; Dent Paul
Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.
Molecular and cellular biology 2003;23(9):3052-66.
2003: Wang Shujie; Wang Zhiliang; Dent Paul; Grant Steven
Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.
Blood 2003;101(9):3648-57.
2003: Yu Chunrong; Rahmani Mohamed; Dai Yun; Conrad Daniel; Krystal Geoffrey; Dent Paul; Grant Steven
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Cancer research 2003;63(8):1822-33.
2003: Leach J Kevin; Qiao Liang; Fang Youwen; Han Song L Y; Gilfor Dpnna; Fisher Paul B; Grant Steven; Hylemon Philip B; Peterson Darrell; Dent Paul
Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3.
Journal of gastroenterology and hepatology 2003;18(4):376-85.
2003: Dent Paul; Yacoub Adly; Contessa Joseph; Caron Ruben; Amorino George; Valerie Kristoffer; Hagan Michael P; Grant Steven; Schmidt-Ullrich Rupert
Stress and radiation-induced activation of multiple intracellular signaling pathways.
Radiation research 2003;159(3):283-300.
2003: Grant Steven; Roberts John D
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(1):15-26.
2003: Rosato Roberto R; Grant Steven
Histone deacetylase inhibitors in cancer therapy.
Cancer biology & therapy 2003;2(1):30-7.
2003: Cartee Leanne; Maggio Sonia C; Smith Rebecca; Sankala Heidi M; Dent Paul; Grant Steven
Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Molecular cancer therapeutics 2003;2(1):83-93.
2003: Wang Shujie; Wang Zhiliang; Grant Steven
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Molecular pharmacology 2003;63(1):232-42.
2003: Dent Paul; Qiao Liang; Gilfor Donna; Birrer Michael; Grant Steven; Fisher Paul B
The regulation of tumor suppressor genes by oncogenes.
Methods in molecular biology (Clifton, N.J.) 2003;222():269-92.
2002: Roberts John D; Smith Mitchell R; Feldman Eric J; Cragg Louise; Grant Steven
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Clinical lymphoma 2002;3(3):184-8.
2002: Yu Chunrong; Dai Yun; Dent Paul; Grant Steven
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Cancer biology & therapy 2002;1(6):674-82.
2002: Grant Steven; Dent Paul
Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors.
Cell cycle (Georgetown, Tex.) 2002;1(6):383-8.
2002: Dai Yun; Landowski Terry H; Rosen Steven T; Dent Paul; Grant Steven
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Blood 2002;100(9):3333-43.
2002: Yu Chunrong; Krystal Geoffrey; Dent Paul; Grant Steven
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2976-84.
2002: Cartee Leanne; Sankala Heidi; Davis Christine; Smith Rebecca; Maggio Sonia; Lin Peck-Sun; Dent Paul; Grant Steven
7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.
International journal of oncology 2002;21(2):351-9.
2002: Rahmani Mohamed; Grant Steven
UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937).
Cell cycle (Georgetown, Tex.) 2002;1(4):273-81.
2002: Cragg Louise H; Andreeff Michael; Feldman Eric; Roberts John; Murgo Anthony; Winning Mary; Tombes Mary Beth; Roboz Gail; Kramer Lora; Grant Steven
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2123-33.
2002: Almenara J; Rosato R; Grant S
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(7):1331-43.
2002: McKallip Robert J; Lombard Catherine; Fisher Michael; Martin Billy R; Ryu Seongho; Grant Steven; Nagarkatti Prakash S; Nagarkatti Mitzi
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
Blood 2002;100(2):627-34.
2002: Qiao Liang; McKinstry Robert; Gupta Seema; Gilfor Donna; Windle Jolene J; Hylemon Philip B; Grant Steven; Fisher Paul B; Dent Paul
Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53.
Hepatology (Baltimore, Md.) 2002;36(1):39-48.
2002: Rahmani Mohamed; Dai Yun; Grant Steven
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Experimental cell research 2002;277(1):31-47.
2002: Cartee L; Smith R; Dai Y; Rahmani M; Rosato R; Almenara J; Dent P; Grant S
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Molecular pharmacology 2002;61(6):1313-21.
2002: McKinstry Robert; Qiao Liang; Yacoub Adly; Dai Yun; Decker Roy; Holt Shawn; Hagan Michael P; Grant Steven; Dent Paul
Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.
Cancer biology & therapy 2002;1(3):243-53.
2002: Wang Zhiliang; Wang Shujie; Dai Yun; Grant Steven
Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).
The Journal of pharmacology and experimental therapeutics 2002;301(2):568-77.
2002: Qiao Liang; Yacoub Adly; Studer Elaine; Gupta Seema; Pei Xin Yan; Grant Steven; Hylemon Philip B; Dent Paul
Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.
Hepatology (Baltimore, Md.) 2002;35(4):779-89.
2002: Dai Yun; Dent Paul; Grant Steven
Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A.
Cell cycle (Georgetown, Tex.) 2002;1(2):143-52.
2002: Qiao Liang; Yacoub Adly; McKinstry Robert; Park Jong Sung; Caron Ruben; Fisher Paul B; Hagan Michael P; Grant Steven; Dent Paul
Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.
Cancer biology & therapy 2002;1(2):168-76.
2002: Decker Roy H; Wang Shujie; Dai Yun; Dent Paul; Grant Steven
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Cancer biology & therapy 2002;1(2):136-44.
2002: Grant Steven; Spiegel Sarah
A chicken-or-egg conundrum in apoptosis: which comes first? Ceramide or PKCdelta?
The Journal of clinical investigation 2002;109(6):717-9.
2002: Rosato Roberto R; Almenara Jorge A; Cartee Leanne; Betts Vicki; Chellappan Srikumar P; Grant Steven
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Molecular cancer therapeutics 2002;1(4):253-66.
2002: Grant Steven; Qiao Liang; Dent Paul
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
Frontiers in bioscience : a journal and virtual library 2002;7():d376-89.
2002: Yu Chunrong; Krystal Geoffrey; Varticovksi Lyuba; McKinstry Robert; Rahmani Mohamed; Dent Paul; Grant Steven
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Cancer research 2002;62(1):188-99.
2002: Grant Steven; Fisher Paul B; Dent Paul
The role of signal transduction pathways in drug and radiation resistance.
Cancer treatment and research 2002;112():89-108.
2001: Qiao L; Leach K; McKinstry R; Gilfor D; Yacoub A; Park J S; Grant S; Hylemon P B; Fisher P B; Dent P
Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression.
Hepatology (Baltimore, Md.) 2001;34(5):906-17.
2001: Rabah D; Grant S; Ma C; Conrad D H
Bryostatin-1 specifically inhibits in vitro IgE synthesis.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(9):4910-8.
2001: Qiao L; Studer E; Leach K; McKinstry R; Gupta S; Decker R; Kukreja R; Valerie K; Nagarkatti P; El Deiry W; Molkentin J; Schmidt-Ullrich R; Fisher P B; Grant S; Hylemon P B; Dent P
Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.
Molecular biology of the cell 2001;12(9):2629-45.
2001: Yu C; Wang Z; Dent P; Grant S
MEK1/2 inhibitors promote Ara-C-induced apoptosis but not loss of Deltapsi(m) in HL-60 cells.
Biochemical and biophysical research communications 2001;286(5):1011-8.
2001: Decker R H; Dai Y; Grant S
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
Cell death and differentiation 2001;8(7):715-24.
2001: Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Cancer research 2001;61(13):5106-15.
2001: Rosato R R; Wang Z; Gopalkrishnan R V; Fisher P B; Grant S
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
International journal of oncology 2001;19(1):181-91.
2001: Yu C; Wang S; Dent P; Grant S
Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.
Molecular pharmacology 2001;60(1):143-54.
2001: Park J S; Qiao L; Su Z Z; Hinman D; Willoughby K; McKinstry R; Yacoub A; Duigou G J; Young C S; Grant S; Hagan M P; Ellis E; Fisher P B; Dent P
Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways.
Oncogene 2001;20(25):3266-80.
2001: Dent P; Grant S
Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):775-83.
2001: Vrana J A; Grant S
Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.
Blood 2001;97(7):2105-14.
2001: Cartee L; Wang Z; Decker R H; Chellappan S P; Fusaro G; Hirsch K G; Sankala H M; Dent P; Grant S
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cancer research 2001;61(6):2583-91.
2001: Harvey S; Decker R; Dai Y; Schaefer G; Tang L; Kramer L; Dent P; Grant S
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):320-30.
2000: Tang L; Boise L H; Dent P; Grant S
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Biochemical pharmacology 2000;60(10):1445-56.
2000: Cartee L; Davis C; Lin P S; Grant S
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.
International journal of radiation biology 2000;76(10):1323-33.
2000: Bondzi C; Grant S; Krystal G W
A novel assay for the measurement of Raf-1 kinase activity.
Oncogene 2000;19(43):5030-3.
2000: Wang Z; Wang S; Fisher P B; Dent P; Grant S
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
Differentiation; research in biological diversity 2000;66(1):1-13.
2000: Schmidt-Ullrich R K; Dent P; Grant S; Mikkelsen R B; Valerie K
Signal transduction and cellular radiation responses.
Radiation research 2000;153(3):245-57.
2000: Cartee L; Vrana J A; Wang Z; Park J S; Birrer M; Fisher P B; Grant S; Dent P
Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway.
International journal of oncology 2000;16(2):413-22.
2000: Roberts J D; Poplin E A; Tombes M B; Kyle B; Spicer D V; Grant S; Synold T; Moran R
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Cancer chemotherapy and pharmacology 2000;45(2):103-10.
1999: Schwarz Y X; Yang M y; Qin D; Wu J; Jarvis W D; Grant S; Burton G F; Szakal A K; Tew J G
Follicular dendritic cells protect malignant B cells from apoptosis induced by anti-Fas and antineoplastic agents.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6442-7.
1999: Vrana J A; Decker R H; Johnson C R; Wang Z; Jarvis W D; Richon V M; Ehinger M; Fisher P B; Grant S
Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
Oncogene 1999;18(50):7016-25.
1999: Oskeritzian C A; Wang Z; Kochan J P; Grimes M; Du Z; Chang H W; Grant S; Schwartz L B
Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(9):5105-15.
1999: Tombes R M; Mikkelsen R B; Jarvis W D; Grant S
Downregulation of delta CaM kinase II in human tumor cells.
Biochimica et biophysica acta 1999;1452(1):1-11.
1999: Wang S; Wang Z; Boise L H; Dent P; Grant S
Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(10):1564-73.
1999: Jarvis W D; Johnson C R; Fornari F A; Park J S; Dent P; Grant S
Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation.
The Journal of pharmacology and experimental therapeutics 1999;290(3):1384-92.
1999: Vrana J A; Kramer L B; Saunders A M; Zhang X F; Dent P; Povirk L F; Grant S
Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
Biochemical pharmacology 1999;58(1):121-31.
1999: Vrana J A; Wang Z; Rao A S; Tang L; Chen J H; Kramer L B; Grant S
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(7):1046-55.
1999: Wang S; Wang Z; Boise L; Dent P; Grant S
Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.
Biochemical and biophysical research communications 1999;259(1):67-72.
1999: Vrana J A; Grant S; Dent P
Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation.
Radiation research 1999;151(5):559-69.
1999: Wang Z; Van Tuyle G; Conrad D; Fisher P B; Dent P; Grant S
Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
Cancer research 1999;59(6):1259-67.
1999: Jarvis W D; Grant S
Protein kinase C targeting in antineoplastic treatment strategies.
Investigational new drugs 1999;17(3):227-40.
1999: Poplin E; Roberts J; Tombs M; Grant S; Rubin E
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Investigational new drugs 1999;17(1):57-62.
1998: Dent P; Jarvis W D; Birrer M J; Fisher P B; Schmidt-Ullrich R K; Grant S
The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(12):1843-50.
1998: Jarvis W D; Grant S
The role of ceramide in the cellular response to cytotoxic agents.
Current opinion in oncology 1998;10(6):552-9.
1998: Jarvis W D; Fornari F A; Tombes R M; Erukulla R K; Bittman R; Schwartz G K; Dent P; Grant S
Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
Molecular pharmacology 1998;54(5):844-56.
1998: Wang Z; Su Z Z; Fisher P B; Wang S; VanTuyle G; Grant S
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Experimental cell research 1998;244(1):105-16.
1998: Wang S; Guo C Y; Castillo A; Dent P; Grant S
Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).
Biochemical pharmacology 1998;56(5):635-44.
1998: Vrana J A; Saunders A M; Chellappan S P; Grant S
Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Differentiation; research in biological diversity 1998;63(1):33-42.
1998: Vrana J A; Rao A S; Wang Z; Jarvis W D; Grant S
Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
International journal of oncology 1998;12(4):927-34.
1998: Grant S; Roberts J; Poplin E; Tombes M B; Kyle B; Welch D; Carr M; Bear H D
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):611-8.
1998: Grant S
Ara-C: cellular and molecular pharmacology.
Advances in cancer research 1998;72():197-233.
1997: Jarvis W D; Fornari F A; Auer K L; Freemerman A J; Szabo E; Birrer M J; Johnson C R; Barbour S E; Dent P; Grant S
Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine.
Molecular pharmacology 1997;52(6):935-47.
1997: Wang S; Vrana J A; Bartimole T M; Freemerman A J; Jarvis W D; Kramer L B; Krystal G; Dent P; Grant S
Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Molecular pharmacology 1997;52(6):1000-9.
1997: Chelliah J; Freemerman A J; Wu-Pong S; Jarvis W D; Grant S
Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
Biochemical pharmacology 1997;54(5):563-73.
1997: Jarvis W D; Auer K L; Spector M; Kunos G; Grant S; Hylemon P; Mikkelsen R; Dent P
Positive and negative regulation of JNK1 by protein kinase C and p42(MAP kinase) in adult rat hepatocytes.
FEBS letters 1997;412(1):9-14.
1997: Bartimole T M; Vrana J A; Freemerman A J; Jarvis W D; Reed J C; Boise L H; Grant S
Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis.
Cell death and differentiation 1997;4(4):294-303.
1997: Freemerman A J; Vrana J A; Tombes R M; Jiang H; Chellappan S P; Fisher P B; Grant S
Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(4):504-13.
1996: Grant S; Turner A J; Freemerman A J; Wang Z; Kramer L; Jarvis W D
Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Experimental cell research 1996;228(1):65-75.
1996: Rao A S; Freemerman A J; Jarvis W D; Chelliah J; Bear H D; Mikkelsen R; Grant S
Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(7):1150-8.
1996: Bear H D; McFadden A W; Kostuchenko P J; Lipshy K A; Hamad G G; Turner A J; Roberts J D; Carr M; Carr S; Grant S
Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
Anti-cancer drugs 1996;7(3):299-306.
1996: Grant S; Freemerman A J; Birrer M J; Martin H A; Turner A J; Szabo E; Chelliah J; Jarvis W D
Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(5):603-13.
1996: Freemerman A J; Turner A J; Birrer M J; Szabo E; Valerie K; Grant S
Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
Molecular pharmacology 1996;49(5):788-95.
1996: Fornari F A; Jarvis D W; Grant S; Orr M S; Randolph J K; White F K; Gewirtz D A
Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin.
Biochemical pharmacology 1996;51(7):931-40.
1996: Jarvis W D; Fornari F A; Traylor R S; Martin H A; Kramer L B; Erukulla R K; Bittman R; Grant S
Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells.
The Journal of biological chemistry 1996;271(14):8275-84.
1996: Verheij M; Bose R; Lin X H; Yao B; Jarvis W D; Grant S; Birrer M J; Szabo E; Zon L I; Kyriakis J M; Haimovitz-Friedman A; Fuks Z; Kolesnick R N
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.
Nature 1996;380(6569):75-9.
1996: Watson N C; Jarvis W D; Orr M S; Grant S; Gewirtz D A
Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death.
International journal of radiation biology 1996;69(2):183-92.
1995: Grant S; Turner A; Nelms P; Yanovich S
Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(5):808-14.
1995: Grant S; Freemerman A J; Gregory P C; Martin H A; Turner A J; Mikkelsen R; Chelliah J; Yanovich S; Jarvis W D
Induction of apoptotic DNA fragmentation and c-jun downregulation in human myeloid leukemia cells by the permeant Ca2+ chelator BAPTA/AM.
Oncology research 1995;7(7-8):381-92.
1994: Jarvis W D; Fornari F A; Browning J L; Gewirtz D A; Kolesnick R N; Grant S
Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells.
The Journal of biological chemistry 1994;269(50):31685-92.
1994: Sung S J; Lin P S; Schmidt-Ullrich R; Hall C E; Walters J A; McCrady C; Grant S
Effects of the protein kinase C stimulant bryostatin 1 on the proliferation and colony formation of irradiated human T-lymphocytes.
International journal of radiation biology 1994;66(6):775-83.
1994: Fornari F A; Jarvis W D; Grant S; Orr M S; Randolph J K; White F K; Mumaw V R; Lovings E T; Freeman R H; Gewirtz D A
Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(7):723-33.
1994: Jarvis W D; Turner A J; Povirk L F; Traylor R S; Grant S
Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.
Cancer research 1994;54(7):1707-14.
1994: Jarvis W D; Povirk L F; Turner A J; Traylor R S; Gewirtz D A; Pettit G R; Grant S
Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Biochemical pharmacology 1994;47(5):839-52.
1994: Grant S; Traylor R; Pettit G R; Lin P S
The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.
Blood 1994;83(3):663-7.
1994: Jarvis W D; Kolesnick R N; Fornari F A; Traylor R S; Gewirtz D A; Grant S
Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(1):73-7.
1994: Grant S; Turner A J; Bartimole T M; Nelms P A; Joe V C; Jarvis W D
Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
Oncology research 1994;6(2):87-99.
1994: Woods K E; Grant S; Yanovich S; Gewirtz D A
Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin.
Cancer chemotherapy and pharmacology 1994;33(6):509-14.
1993: Grant S; Traylor R; Pettit G R; Lin P S
Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors.
Cytokine 1993;5(5):490-7.
1993: McCrady C W; Li F; Pettit G R; Grant S
Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
Experimental hematology 1993;21(7):893-900.
1992: Grant S; Jarvis W D; Turner A J; Wallace H J; Pettit G R
Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts.
British journal of haematology 1992;82(3):522-8.
1992: Grant S; Jarvis W D; Swerdlow P S; Turner A J; Traylor R S; Wallace H J; Lin P S; Pettit G R; Gewirtz D A
Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Cancer research 1992;52(22):6270-8.
1992: Li F; Grant S; Pettit G R; McCrady C W
Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor.
Blood 1992;80(10):2495-502.
1992: Grant S; Traylor R; Bhalla K; McCrady C; Pettit G R
Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(5):432-9.
1992: Boise L H; Grant S; Westin E H
Altered expression of cell cycle related genes including c-myb in a subclone of HL-60 that exhibits reversible differentiation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(1):53-61.
1991: Grant S; Boise L; Westin E; Howe C; Pettit G R; Turner A; McCrady C
In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Biochemical pharmacology 1991;42(4):853-67.
1991: Grant S; Pettit G R; Howe C; McCrady C
Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(5):392-8.
1991: Grant S; Arlin Z; Gewirtz D; Feldman E
Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(4):336-9.
1991: McCrady C W; Staniswalis J; Pettit G R; Howe C; Grant S
Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF.
British journal of haematology 1991;77(1):5-15.
1991: Grant S; Bhalla K; McCrady C
Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Leukemia research 1991;15(4):205-13.
1990: Grant S; Bhalla K; Arlin Z; Howe C W
The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Experimental hematology 1990;18(1):41-8.
1990: Grant S; Howe C; Kuczynski T
Selective eradication of leukemic (L-CFU) versus normal (CFU-GM) myeloid progenitors in suspension culture utilizing a prolonged exposure to 1-B-D arabinofuranosylcytosine (Ara-C) and deoxycytidine (dCyd).
Progress in clinical and biological research 1990;333():69-77.
1990: Grant S
Biochemical modulation of cytosine arabinoside.
Pharmacology & therapeutics 1990;48(1):29-44.

Sign-in to see more